Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Medtronic
Boehringer Ingelheim
McKinsey
Express Scripts

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Volitinib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Volitinib?

Volitinib is an investigational drug.

There have been 24 clinical trials for Volitinib. The most recent clinical trial was a Phase 1 trial, which was initiated on July 25th 2017.

The most common disease conditions in clinical trials are Adenocarcinoma, Carcinoma, Renal Cell, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, Hutchison Medipharma Limited, and National Cancer Institute (NCI).

There are six US patents protecting this investigational drug and one hundred and one international patents.

Recent Clinical Trials for Volitinib
TitleSponsorPhase
A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the BodyParexelPhase 1
A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the BodyAstraZenecaPhase 1
A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With FamotidineParexelPhase 1

See all Volitinib clinical trials

Clinical Trial Summary for Volitinib

Top disease conditions for Volitinib
Top clinical trial sponsors for Volitinib

See all Volitinib clinical trials

US Patents for Volitinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Volitinib   Start Trial Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor Hutchison Medipharma Limited (Pudong, Shanghai, CN)   Start Trial
Volitinib   Start Trial Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor Hutchison Medipharma Limited (Pudong, Shanghai, CN)   Start Trial
Volitinib   Start Trial Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor AstraZeneca AB (Sodertalje, SE)   Start Trial
Volitinib   Start Trial Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor AstraZeneca AB (Sodertalke, SE)   Start Trial
Volitinib   Start Trial Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor AstraZeneca AB (Sodertalje, SE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Volitinib

Drugname Country Document Number Estimated Expiration Related US Patent
Volitinib Australia 2010338712 2029-12-31   Start Trial
Volitinib Australia 2015203480 2029-12-31   Start Trial
Volitinib Brazil 112012016129 2029-12-31   Start Trial
Volitinib Canada 2785749 2029-12-31   Start Trial
Volitinib China 102906092 2029-12-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Harvard Business School
Baxter
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.